We are international
Donate
TEXT SIZE   

ask_dr_durie_banner

 

Have a question? Submit it to AskDrDurie@myeloma.org!
 

facebook
googleplus
twitter
youtube


IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org! For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org.

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!


 

 

 

#Ask Dr. Durie
previous     next      view all

05.19.16   What is the new Black Swan project that studies families with myeloma?

In this week’s video, Dr. Brian Durie unveils a new BSRI project which studies genetic factors (though there are few) that are linked to myeloma.

BOTTOM LINE: 

If we identify genetic factors in MM, we can refine treatments accordingly.


05.12.16   What is this new Black Swan project called iStopMM?

In this week’s video, Dr. Brian Durie describes how the iStopMM study aims to prevent myeloma in the entire adult population of adults who are age 40 or over in Iceland.

BOTTOM LINE: While a seemingly lofty goal, iStopMM may bridge the pathway to eliminating myeloma.


05.05.16   Is it worth the risk of developing a secondary cancer after ASCT?

In this week’s Ask Dr. Durie, Dr. Brian Durie discusses how to learn about your own risk factors for secondary cancers when undergoing MM treatment.

BOTTOM LINE:

Know your own risk factors and discuss the pros and cons with your doctor.


04.28.16   How long does it take to assess if a particular treatment is working?

In this week’s video, Dr. Brian Durie provides insight on how to assess response to various myeloma treatments.

BOTTOM LINE:

By checking M-protein levels after each cycle of treatment, we can assess the true benefits of each therapy.


04.21.16   How common are low platelet counts after autologous stem cell transplant?

In this week’s video, Dr. Brian Durie explains that patients should keep a close eye on their platelet counts after undergoing a stem cell transplant.

The BOTTOM LINE: 

If platelet counts drop too low, therapy adjustments should be considered.


04.14.16   Does immune therapy work for high-risk myeloma?

In this week’s video, Dr. Brian Durie discusses how immune therapies work in the treatment of myeloma.

BOTTOM LINE:

Best bets to fight high-risk myeloma are therapies that replace, rather than manipulate, the immune system. 


04.07.16   Do all myeloma patients become high-risk at some point?

In this week’s video, Dr. Brian Durie answers questions about high-risk multiple myeloma.

BOTTOM LINE:

Over time, different myeloma patterns emerge. 


03.31.16   What is the status of the measles vaccine trial?

In this week’s video, Dr. Brian Durie discusses the use of virus trials in the treatment of multiple myeloma.

BOTTOM LINE:

The virus trials are generating excitement. Contact the IMF to learn more.


03.24.16   If no treatment for multiple myeloma is recommended, is a bone marrow biopsy necessary?

In this week’s video, Dr. Durie answers a question about whether a patient should undergo a bone marrow biopsy, even if treatment is not recommended at the time.

Bottom Line: 

If you are unsure about diagnosis, treatment, or testing, consult an expert.


03.17.16   After relapse, I’m responding well to Rev/dex. Should I continue this treatment?

In this week's video, Dr. Brian Durie addresses if patients should continue certain treatments.

Bottom Line: 

When the disease is controlled, ongoing maintenance is still a good choice. 


previous     next      view all